INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 146 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $735 | +293.0% | 54,751 | +261.1% | 0.07% | +257.9% |
| Q4 2022 | $187 | -99.9% | 15,163 | +208.3% | 0.02% | -68.3% |
| Q1 2020 | $310,000 | +30.8% | 4,918 | +108.5% | 0.06% | +46.3% |
| Q4 2018 | $237,000 | -71.2% | 2,359 | -65.3% | 0.04% | -73.7% |
| Q2 2017 | $824,000 | +99.0% | 6,798 | +85.6% | 0.16% | +60.8% |
| Q1 2017 | $414,000 | – | 3,662 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |